The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
Herlinde Dumez
No relevant relationships to disclose
Andrea Gombos
No relevant relationships to disclose
Patrick Schöffski
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Thierry Gil
No relevant relationships to disclose
Christof Vulsteke
No relevant relationships to disclose
Marie-Anne Meeus
Employment or Leadership Position - Boehringer Ingelheim
Jessica Cescutti
Employment or Leadership Position - Boehringer Ingelheim
Gerd Michael Munzert
Employment or Leadership Position - Boehringer Ingelheim
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Ahmad Awada
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim